$NVO
Novo Nordisk A/S
Danish pharma giant behind Ozempic and Wegovy weight-loss treatments.
NVO key facts as of November 14, 2026
- Latest AI research report
- NVO Stock: Pipeline, Valuation and Key Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Hold (0 Strong Buy, 3 Buy, 10 Hold, 1 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $42.33 mean (range $40.00 to $47.00) (as of November 17, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
NVO Stock: Pipeline, Valuation and Key Risks
Novo Nordisk reported a quarterly EPS beat and submitted etavopivat for regulatory review, adding to its pipeline beyond diabetes and obesity medicines. Yet analyst targets sit close to the Friday close, the shares remain well below their 52-week high, and available financial feeds contain conflicting per-share figures.
Previous Reports
NVO FAQ
What is StockAlpha's latest view on NVO?
StockAlpha's latest AI research report on Novo Nordisk A/S (NVO), "NVO Stock: Pipeline, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Novo Nordisk reported a quarterly EPS beat and submitted etavopivat for regulatory review, adding to its pipeline beyond diabetes and obesity medicines. Yet analyst targets sit close to the Friday close, the shares remain well below their 52-week high, and available financial feeds contain conflicting per-share figures.
When was the NVO research last updated?
The most recent NVO report was published on November 14, 2026.
What do analysts expect for NVO?
As of November 1, 2026, the analyst consensus on NVO is Hold (0 Strong Buy, 3 Buy, 10 Hold, 1 Sell, 0 Strong Sell). As of November 17, 2026, the analyst price target is $42.33 mean (range $40.00 to $47.00).
Is this NVO research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Novo Nordisk A/S into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Novo Nordisk A/S's peers: Today's sector-level news and moves around the stock